Investorideas.com  big ideas for global investors Search www.investorideas.com
   Member Access       Sign-up       Newsfeeds        Companies        Stock Directories       Research       Video       Funding   




Category: Investment, Biotech, Pharma

Biotech News Alert: Q & A Interview with C.E.O of Sunshine Biopharma (OTCQB: SBFM) Discussing Recent News of Improved Effectiveness of Lead Compound Adva-27a

Ideas get bigger when you share them...

Visit this company: Sunshine Biopharma Inc.

New York, NY - Point Roberts, WA - April 14, 2014 (Investorideas.com Biotech Newswire) Investorideas.com, a global news source covering leading sectors including biotech and pharma, issues an exclusive Q&A interview with the CEO of Sunshine Biopharma Inc. ( OTCQB: SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.

Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner

Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma shares insights into recent developments with the company’s lead compound, Adva-27a.

Interview:

Q: Investorideas.com

The company recently announced improved effectiveness of your lead compound Adva-27a. Can you explain to investors what the results were and what that means moving forward?

A: Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma

We resolved the two isomeric forms of our lead anticancer compound, Adva-27a, and as a result the specific activity of the drug candidate has increased 9.5-fold. We had previously announced that the concentration at which Adva-27a inhibited 50% of the activity of Topoisomerase II, an enzyme that cancer cells use to proliferate, (IC50) was 13.7 micromolar (see press release issued on October 5, 2011). As a result of this recent laboratory development Adva-27a’s IC50 has dropped 9.5-fold, to 1.44 micromolar.

This implies that significantly lower quantities of the drug can be used to achieve the same effect. In the long run, this could also mean lower therapeutic dosages for our future breast cancer and pancreatic cancer patients, which theoretically should result in reduced side-effects.

Q: Investorideas.com

Will this improved effectiveness apply to all the cancers you are targeting or just one specific target?

A: Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma

Yes, theoretically this improved effectiveness applies to all cancer types in which Adva-27a is effective.

Q: Investorideas.com

What triggered you toresolve the two isomeric forms of your lead anticancer compound, Adva-27a?.

A: Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma

Resolving the isomeric forms of a lead compound is usually one of the matters addressed at the final stages of drug synthesis. Not all compounds have isomeric forms. Adva-27a happens to be a compound that does, owing to the presence of a carbohydrate moiety which is important for the anticancer activity of the molecule.

Q: Investorideas.com

You announced in late January that the company is now targeting pancreatic cancer as a second indication for Adva-27a, what is the significance of a second indication?

A: Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma

Pancreatic cancer has an extremely poor prognosis. Most pancreatic cancer patients will die within one year of diagnosis. Cancer of the pancreas is the fourth most common cause of cancer-related deaths in the United States. Recently, the Pancreatic Cancer Action Network released a special report entitled, ‘The Alarming Rise of Pancreatic Cancer Deaths in the United States: Why We Need to Stem the Tide Today’. The alarming findings presented in the report included the fact that by the year 2020, and possibly as early as 2015, pancreatic cancer will move from the fourth leading cause of cancer deaths to the second leading cause of cancer deaths in the United States. It is the aggressive nature and lack of effective therapy that lead us to apply Adva-27a for use against pancreatic cancer.

About Adva-27a

Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.

About Sunshine Biopharma Inc. ( OTCBB: SBFM )

Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a, which is currently targeted for multidrug resistant cancer.

www.sunshinebiopharma.com

About InvestorIdeas.com:

InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.

Follow Investorideas.com on Twitter   http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook   http://www.facebook.com/Investorideas

Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com

Sign up for our free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Become an Investorideas.com Member and use our online stock directories to research stocks - waters stocks, renewable energy, tech, mobile, mining stocks and more… http://www.investorideas.com/membership/

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure - Disclosure: SBFM effective December 3, 2013 news and content publication (one hundred thousand shares of 144 stock per 3 month period for a total of six months) More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 . Global investors must adhere to regulations of each country.

800-665-0411 -   Source - www.investorideas.com


Free News Alerts
Email:  





TOP

Investor Ideas © 2000 - 2014 InvestorIdeas.com®, ECON

Sign up here

login | logout | about us | contact | disclaimer / disclosure |
advertise | company profile directory | partners / links |
job search | privacy policy | trade | services | sitemap |